108 related articles for article (PubMed ID: 17344911)
1. The outcome of intensive induction therapy in patients >or=70 years with acute myeloid leukemia.
Gupta V; Xu W; Keng C; Alibhai SM; Brandwein J; Schimmer A; Schuh A; Yee K; Minden MD
Leukemia; 2007 Jun; 21(6):1321-4. PubMed ID: 17344911
[No Abstract] [Full Text] [Related]
2. [The therapy of acute myeloid leukemia in patients of advanced age].
Kern W; Schoch C; Fonatsch C; Heinecke A; Wörmann B; Büchner T; Hiddemann W
Dtsch Med Wochenschr; 1999 Aug; 124(34-35):1005-14. PubMed ID: 10488328
[No Abstract] [Full Text] [Related]
3. Therapy of acute myeloid leukemia in children.
Nesbit ME; Woods WG
Leukemia; 1992; 6 Suppl 2():31-5. PubMed ID: 1578938
[TBL] [Abstract][Full Text] [Related]
4. "3+7" therapy for the treatment of acute myeloid leukemia. CON.
Estey EH
Clin Adv Hematol Oncol; 2005 Feb; 3(2):129-132, 141. PubMed ID: 16173152
[No Abstract] [Full Text] [Related]
5. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
6. Comparison of survival. Chemotherapeutically treated and untreated older patient with acute myeloid leukemia.
Siddiqui T; Durkin WJ; Conley NS; Doughney KB; Favis GR; Weiss R; Smith AE
J Fla Med Assoc; 1994 Jul; 81(7):475-7. PubMed ID: 7964574
[TBL] [Abstract][Full Text] [Related]
7. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.
Sousa AB; Fernandes JP; Costa I; Ferreira G; Nunes O; Ribeiro P; Neves A; Cruz E; Aveiro F; Rodrigues AS; Bernardo M; Conduto A; Gonçalves AJ; Monteiro A; Sousa M; Soares VH; Veiga J; Gouveia J
Hematol Cell Ther; 1998 Apr; 40(2):63-6. PubMed ID: 9615248
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia in the elderly: evaluation of overall survival in 69 consecutive patients.
Veneri D; Zanetti F; Franchini M; Ambrosetti A; Pizzolo G
Haematologica; 2002 Apr; 87(4):447-8. PubMed ID: 11940493
[No Abstract] [Full Text] [Related]
11. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
[TBL] [Abstract][Full Text] [Related]
12. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
[TBL] [Abstract][Full Text] [Related]
14. Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.
Buccisano F; Maurillo L; Del Poeta G; Gattei V; Amadori S; Venditti A
Haematologica; 2006 Dec; 91(12 Suppl):ELT14; author reply ELT15. PubMed ID: 17194674
[No Abstract] [Full Text] [Related]
15. The approach to the elderly patient with acute myeloid leukemia.
Stone RM; Mayer RJ
Hematol Oncol Clin North Am; 1993 Feb; 7(1):65-79. PubMed ID: 7680642
[TBL] [Abstract][Full Text] [Related]
16. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy for acute myelogenous leukemia.
Kalaycio M
Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: 15610659
[No Abstract] [Full Text] [Related]
18. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.
Schlenk RF; Fröhling S; Hartmann F; Fischer JT; Glasmacher A; Del Valle F; Götze K; Nerl C; Schoch R; Pralle H; Mergenthaler HG; Hensel M; Koller E; Kirchen H; Matzdorff A; Salwender H; Biedermann HG; Kremers S; Haase D; Benner A; Döhner K; Döhner H
Leukemia; 2006 Apr; 20(4):748-50. PubMed ID: 16437135
[No Abstract] [Full Text] [Related]
19. Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia.
Oriol A; Ribera JM; Brunet S; Esteve J; Bueno J; Llorente A
Haematologica; 2003 Feb; 88(2):229-30. PubMed ID: 12604418
[No Abstract] [Full Text] [Related]
20. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
